Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

ABSTRACT:

Importance

Treatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon.

Objective

To determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.

Design, setting, and participants

Open-label, nonrandomized, uncontrolled phase 3 trial conducted at 34 treatment centers in the United States and Puerto Rico (August 2012-November 2013) evaluating treatment with sofosbuvir and ribavirin among patients with HCV genotypes 1, 2, or 3 and concurrent HIV. Patients were required to be receiving ART with H

SUBMITTER: Sulkowski MS 

PROVIDER: S-EPMC4997358 | biostudies-literature | 2014 Jul 23-30

REPOSITORIES: biostudies-literature